Moral Injury in Medicine: What It Means for Ketamine Care

A Hidden Crisis Beneath the Surface of Psychiatric Care

Ahead of the American Psychiatric Association's 2026 annual meeting, Psychiatric Times is spotlighting a topic that rarely makes headlines but runs deep through the profession: moral injury. Distinct from burnout — though often tangled with it — moral injury refers to the psychological damage caused when clinicians are forced to act against their own ethical values, witness institutional failures, or feel complicit in harm they couldn't prevent.

The coverage explores how betrayal trauma and bystander guilt accumulate silently within healthcare systems, creating a kind of internal fracture in providers who feel trapped between what they know is right and what the system allows them to do. The APA's decision to center this topic reflects a growing recognition that clinician well-being is not a peripheral issue — it's foundational to the quality of care patients receive.

For those navigating ketamine therapy, this conversation is more relevant than it might first appear.

Why This Matters in the Ketamine Therapy Landscape

Ketamine and esketamine (Spravato) occupy an unusual position in psychiatry: they work fast, they work differently, and for a significant subset of patients with treatment-resistant depression, PTSD, and suicidal ideation, they work when nothing else has. But the field is young, still somewhat marginalized within mainstream psychiatry, and heavily dependent on individual clinicians who are willing to navigate reimbursement headaches, regulatory ambiguity, and institutional skepticism.

These are exactly the conditions that breed moral injury. A psychiatrist who believes a patient needs ketamine but cannot get it covered, approved, or supported by their hospital system is living the textbook definition of moral distress. So is an anesthesiologist running a ketamine clinic in isolation, uncertain whether the broader medical establishment views their work as legitimate or exploitative. And so is a nurse or therapist watching a patient cycle through SSRIs for years when an alternative exists but feels inaccessible.

When clinicians carry unprocessed moral injuries, the downstream effects on patient care are real. Providers experiencing moral exhaustion may reduce their availability, narrow their patient panels, leave the field entirely, or — perhaps most subtly — become less emotionally present during the integration and monitoring sessions that are critical to ketamine's therapeutic effectiveness.

What Psychiatry Is Learning About Recovery From Moral Injury

The APA preview piece highlights that moral injury doesn't resolve through standard stress management or even traditional therapy alone. The wound is ethical and relational — it often requires acknowledgment from institutions, peer witness, and sometimes a restructuring of the professional environment itself. Emerging approaches include peer support models, narrative medicine, and trauma-informed supervision structures.

Interestingly, ketamine's own therapeutic mechanisms — promoting neuroplasticity, disrupting rigid negative thought patterns, creating psychological flexibility — are being studied in the context of moral injury and PTSD in military and first-responder populations. While research in healthcare workers is still nascent, the overlap is conceptually compelling. Some clinicians who treat patients with ketamine are, quietly, exploring it themselves for their own treatment-resistant conditions.

This creates a potentially powerful feedback loop: providers who understand ketamine's effects experientially, and who have done their own psychological work, may be uniquely positioned to support patients through the disorienting and transformative process of infusion therapy.

What Patients and Caregivers Can Do With This Information

You may not be able to fix the systemic conditions driving moral injury in psychiatry, but you can be a more informed and empathetic participant in your own care. Here's what this research moment suggests practically:

• Ask about your clinic's support structures. Does your ketamine provider work within a team, or largely alone? Isolated practitioners are at higher risk for burnout. Clinics with psychiatric supervision, therapist collaboration, and regular case consultation tend to offer more stable, comprehensive care.
• Notice staff retention. High turnover in a ketamine clinic is a signal worth paying attention to. Continuity of care matters in a treatment that is deeply personal and often emotionally intense.
• Advocate for your providers, too. If you've had a meaningful experience with ketamine therapy, sharing that story — in reviews, in advocacy spaces, with insurers — contributes to a culture that validates clinicians doing this work. Moral injury is often compounded by invisibility. Recognition matters.
• Seek providers who reflect on ethics. Clinicians who engage seriously with the moral dimensions of their work — including questions of access, equity, and appropriate use of ketamine — are likely to be more thoughtful partners in your care than those who treat it purely as a procedural service.

The APA's attention to moral injury signals a maturing field grappling honestly with the human costs of healthcare. For ketamine therapy to fulfill its potential, it needs clinicians who are psychologically whole enough to show up fully for patients in some of their most vulnerable moments. That starts with taking provider well-being as seriously as patient outcomes.

Read the original Psychiatric Times coverage: Moral Injuries: An APA Preview.